US Stock MarketDetailed Quotes
ANRO Alto Neuroscience
- 4.310
- +0.220+5.38%
Close Nov 22 16:00 ET
- 4.450
- +0.140+3.24%
Post 20:01 ET
116.24MMarket Cap-2023P/E (TTM)
4.429High4.100Low362.32KVolume4.120Open4.090Pre Close1.56MTurnover1.87%Turnover RatioLossP/E (Static)26.97MShares24.00052wk High0.70P/B83.57MFloat Cap3.61052wk Low--Dividend TTM19.39MShs Float24.000Historical High--Div YieldTTM8.04%Amplitude3.610Historical Low4.305Avg Price1Lot Size
About Alto Neuroscience Company
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.
Company Profile
SymbolANRO
Company NameAlto Neuroscience
Listing DateFeb 2, 2024
Issue Price16.00
Founded2019
CEODr. Amit Etkin, M.D.
MarketNYSE
Employees63
Fiscal Year Ends12-31
Address650 Castro Street,Suite 450
CityMountain View
ProvinceCalifornia
CountryUnited States of America
Zip Code94041
Phone1-650-200-0412
Company Executives
- Name
- Position
- Salary
- Dr. Amit Etkin, M.D.
- President, Chief Executive Officer and Chairman of the Board
- 1.86M
- Michael Conick Hanley, Jr
- Chief Operating Officer
- --
- Nicholas Conrad Smith
- Chief Financial Officer and Principal Accounting Officer
- 1.60M
- Adam Savitz
- Chief Medical Officer
- 1.24M
- Mahalakshmi Radhakrishnan, M.D.
- Independent Director
- --
- Christopher Nixon Cox
- Independent Director
- --
- Dr. Po Yu Chen
- Independent Director
- --
- Dr. Husseini Manji
- Independent Director
- --
- Gwill York
- Independent Director
- 53.68K
- Andrew Dreyfus
- Independent Director
- 107.37K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data